Researchers from the Broad, Abbvie, and Calico Life Sciences have developed a new cancer immunotherapy candidate — now being tested in an early-stage clinical trial — that may provoke a potent response in both cancer and immune cells. Project leaders...

Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators...